Pfizer presented data ​on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its ...

Pfizer’s experimental drug, berobenatide, is designed to stay attached longer to a blood protein called albumin, helping ...

Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and ...

Pfizer revealed data on its new obesity drug berobenatide, following its acquisition of Metsera. The monthly dose showed ...

The pharma company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry leader.

Pfizer announced Friday that it is discontinuing development of its twice-daily weight loss pill danuglipron after a clinical trial showed "high rates" of adverse side effects among users. The ...

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost significant weight but had trouble tolerating the ...

Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal ...

A rare hantavirus outbreak on an Atlantic cruise ship has reignited conspiratorial Covid-era misinformation, with posts sharing files from Pfizer and the World Health Organization (WHO) as supposed ...

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.